Overview

Study Of Ispinesib In Subjects With Breast Cancer

Status:
Completed
Trial end date:
2006-08-25
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to find how breast cancer responds to the investigational drug, Ispinesib. An investigational drug is a drug that has not been approved by the Food and Drug Administration (FDA) and is available for research use only. In particular, this study will try is to find the answers to the following research questions: 1. Does breast cancer respond to Ispinesib? 2. What are the side effects of Ispinesib? 3. How much Ispinesib is in the blood at specific times after it is taken?
Phase:
Phase 2
Details
Lead Sponsor:
GlaxoSmithKline